VIP Peptide: What It Is and Its U.S. Regulatory Status

What is VIP?

Vasoactive intestinal peptide (VIP) is a naturally occurring neuropeptide made of 28 amino acids. It is not FDA-approved, and no FDA-approved product contains it. A synthetic form of VIP, called aviptadil, has been tested in clinical trials but has not been approved by the FDA.

VIP was first isolated from the intestine in 1970 by Sami Said and Viktor Mutt, which is where its name comes from. It is now known to be made in many tissues, including the brain, gut, lungs and heart, and by some immune cells.

How it works

VIP belongs to the same peptide family as glucagon and secretin. It acts on two receptors, called VPAC1 and VPAC2. Through them it relaxes smooth muscle, widens blood vessels, increases the release of water and salts into the intestine, and dampens some immune responses. These wide-ranging effects are why it has been studied in lung and inflammatory conditions.

Research history: aviptadil and COVID-19

The largest recent trials of VIP used aviptadil in people hospitalized with COVID-19. NRx Pharmaceuticals sought emergency use authorization for its aviptadil product, Zyesami. The FDA declined that request in November 2021 and declined a second request for a narrower group of critically ill patients.

The NIH-sponsored ACTIV-3b (TESICO) trial then tested intravenous aviptadil in 461 adults with COVID-19 and acute respiratory failure. The trial's independent monitoring board recommended stopping it for futility in May 2022. As reported in The Lancet Respiratory Medicine in 2023, recovery at 90 days was no better than with placebo, and deaths through day 90 were 38 percent with aviptadil and 36 percent with placebo.

U.S. regulatory status

Current status: Not FDA-approved.

VIP is listed in Category 1, bulk drug substances under evaluation, on the FDA's list of substances nominated for compounding (updated May 14, 2026). This means the FDA has not yet decided whether to add VIP to the 503A bulks list. Under current FDA policy, pharmacies may compound with a Category 1 substance only if specific conditions are met, such as sourcing it from a registered manufacturer with a valid certificate of analysis.

Category 1 status is not an approval. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are sold.

Products sold online as "research chemicals" or labeled "for research purposes only" are not approved medicines, and the FDA has not reviewed their identity, purity or quality.

Documented safety information

Because VIP widens blood vessels and acts on the gut, its known side effects in aviptadil trials were mainly low blood pressure and diarrhea. In preliminary TESICO data, low blood pressure was reported in about 25 percent of aviptadil patients compared with about 19 percent on placebo. The FDA has not evaluated the long-term safety of VIP products used outside clinical trials.

Why Peptide Labs does not sell VIP

Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply VIP, and we do not point readers to anyone who does.

For personal medical questions, including questions about VIP, the right person to ask is a licensed healthcare provider.

Related reading

See the full list of compound profiles in the Peptide Guide. Other immune-related peptides in the guide include thymosin alpha-1 and LL-37. For the legal background, read whether peptides are legal in the U.S. For another peptide studied in the gut, see larazotide, an investigational drug tested in celiac disease.